Immunological examination of peripheral blood in patients with colorectal cancer compared to healthy controls

References

• Bates GJ, Fox SB, Han C, et al. (2006). Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol., 24, 5373–5380. doi:10.1200/JCO.2006.05.9584.
   PubMed Web of Science ®Google Scholar
• Bayhan Z, Simşek T, Ergül E, et al. (2014). Serum cytokine levels in patients with colorectal cancers according to tumor stages and VEGF gene polymorphism. Hepatogastroenterology, 61, 1889–1894.
   PubMedGoogle Scholar
• Caligiuri MA. (2008). Human natural killer cells. Blood, 112(3), 461–469.
   PubMed Web of Science ®Google Scholar
• Comerci JT, Runowicz CD, Flander KC, et al. (1996). Altered expression of transforming growth factor-β1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix. Cancer, 77, 1107–1114. doi:10.1002/(SICI)1097-0142(19960315)77:6<1107::AID-CNCR16>3.0.CO;2-5.
   PubMed Web of Science ®Google Scholar
• Cools N, Van Tendeloo VF, Smits EL, et al. (2008). Immunosuppression induced by immature dendritic cells is mediated by TGF-beta/IL-10 double-positive CD4+ regulatory T cells. J Cell Mol Med, 12, 690–700. doi:10.1111/j.1582-4934.2007.00084.x.
   PubMed Web of Science ®Google Scholar
• De Jong EC, Vieira PL, Kalinski P, et al. (2002). Microbial compounds selectively induce Th1 cell‐promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell‐polarizing signals. J Immunol, 168, 1704–1709.
   PubMed Web of Science ®Google Scholar
• Eder IE, Stenzl A, Hobisch A, et al. (1996). Transforming growth factors-β1 and β2 in serum and urine from patients with bladder carcinoma. J Urol, 156, 953–957. doi:10.1016/S0022-5347(01)65670-2.
   PubMed Web of Science ®Google Scholar
• Fernandez-Messina L, Reyburn HT, Vales-Gomez M. (2012). Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Front Immunol, 3, 299.
   PubMed Web of Science ®Google Scholar
• Finek J, Hoch J, Kala Z, et al. (2017). Zhoubný novotvar kolorekta (C18-20). In: Vyzula, R., Arenberger, P., Babjuk, M, et al., eds. Modrá kniha, Brno: Masaryk Memorial Cancer Institute. 23–35.
   Google Scholar
• Friess H, Yamanaka Y, Buchler M, et al. (1993). Enhanced expression of transforming growth factor-β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology, 105, 1846–1856. doi:10.1016/0016-5085(93)91084-U.
   PubMed Web of Science ®Google Scholar
• Goi T, Nakazawa T, Hirono Y, et al. (2015). The prognosis was poorer in colorectal cancers that expressed both VEGF and PROK1(No correlation coefficient between VEGF and PROK1). Oncotarget, 6, 28790–28799. doi:10.18632/oncotarget.4744.
   PubMedGoogle Scholar
• Grievnikkov S, Greten F, Karin MI. (2010). Immunity, inflammation, and cancer. Cell, 140, 883–899. doi:10.1016/j.cell.2010.01.025.
   PubMed Web of Science ®Google Scholar
• Inoue S, Leitner WW, Golding B, et al. (2006). Inhibitory effects of B cells on antitumor immunity. Cancer Res, 66, 7741–7747.
   PubMed Web of Science ®Google Scholar
• Kim JE, Hong YS, Kim HJ, et al. (2017). Microsatellite instability was not associated with survival in stage III colon cancer treated with adjuvant chemotherapy of Oxaliplatin and infusional 5-Fluorouracil and Leucovorin (FOLFOX). Ann Surg Oncol, 2017, 1289–1294. doi:10.1245/s10434-016-5682-5.
   Google Scholar
• Krzewski K, Coligan JE. (2012). Human NK cell lytic granules and regulation of their exocytosis. Front Immunol, 3, 335.
   PubMed Web of Science ®Google Scholar
• Lanier LL. (1998). NK cell receptors. Annu Rev Immunol, 16, 359–393. doi:10.1146/annurev.immunol.16.1.359.
   PubMed Web of Science ®Google Scholar
• Li Q, Lao X, Pan Q, Ning N, et al. (2011). Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res, 17, 4987–4995.
   PubMed Web of Science ®Google Scholar
• Li Q, Teitz-Tennenbaum S, Donald EJ, et al. (2009). In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol, 183, 3195–3203.
   PubMed Web of Science ®Google Scholar
• Ljunggren HG. (2008). Cancer immunosurveillance: NKG2D breaks cover. Immunity, 28, 492–494. doi:10.1016/j.immuni.2008.03.007.
   PubMed Web of Science ®Google Scholar
• Logan-Collins JM, Lowy AM, Robinson-Smith TM, et al. (2008). VEGF expression predicts survival in patients with peritoneal surface metastases from mucinousadenocarcinoma of the appendix and colon. Ann Surg Oncol, 15, 738–744. doi:10.1245/s10434-007-9699-7.
   PubMed Web of Science ®Google Scholar
• López-Soto A, Huergo-Zapico L, Galván JA, et al. (2013). Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor. J Immunol, 190, 4408–4419. doi:10.4049/jimmunol.1202950.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Kobayashi T, Ichiyama K, et al. (2007). Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells. J Immunol, 179, 2170–2179. doi:10.4049/jimmunol.179.4.2170.
   PubMed Web of Science ®Google Scholar
• Matsushita T, Yanaba K, Bouaziz JD, et al. (2008). Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest, 118, 3420–3430.
   PubMed Web of Science ®Google Scholar
• Mehrabani D, Shamsdin SA, Dehghan A. (2014). Clinical significance of serum vascular endothelial growth factor and complement 3a levels in patients withcolorectal cancer in southern Iran. Asian Pac J Cancer Prev, 15, 9713–9717. doi:10.7314/APJCP.2014.15.22.9713.
   PubMedGoogle Scholar
• Muraoka-Cook RS, Dumont N, Arteaga CL. (2005). Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res, 11, 937–943.
   PubMed Web of Science ®Google Scholar
• Pende D, Cantoni C, Rivera P, et al. (2001). Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol, 31, 1076–1086. doi:10.1002/1521-4141(200104)31:4<1076::AID-IMMU1076>3.0.CO;2-Y.
   PubMed Web of Science ®Google Scholar
• Perricone MA, Smith KA, Claussen KA, et al. (2004). Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother, 27, 273–281.
   PubMed Web of Science ®Google Scholar
• Qin Z, Richter G, Schüler T, et al. (1998). B cells inhibit induction of T cell-dependent tumor immunity. Nat Med, 4, 627–630. doi:10.1038/nm0598-627.
   PubMed Web of Science ®Google Scholar
• Raulet DH, Gasser S, Gowen BG, et al. (2013). Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol, 31, 413–41.
   PubMed Web of Science ®Google Scholar
• Sadahiro S, Suzuki T, Maeda Y, et al. (2010). Effects of preoperative immunochemoradiotherapy and chemoradiotherapy on immune responses in patients with rectal adenocarcinoma. Anticancer Res, 30, 993–999.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Geginat J, Lanzavecchia A. (2004). Central memory and effector memory t cell subsets : Function, generation, and maintenance. Annu Rev Immunol, 22, 745–763.
   PubMed Web of Science ®Google Scholar
• Sawan S, Burt DJ, Stern PL, et al. (2010). Circulating regulatory T cells in endometrial cancer: a role for age and menopausal status. Immunol Invest, 40(1), 62–75.
   PubMed Web of Science ®Google Scholar
• Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014; 35: 51–60.
   PubMed Web of Science ®Google Scholar
• Schioppa T, Moore R, Thompson RG, et al. (2011). B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci Usa, 108, 10662–10667.
   PubMed Web of Science ®Google Scholar
• Seder RA, Ahmed R. (2003). Similarities and differences in CD4+ and CD8+ effector and memory t cell generation. Nat Immunol, 4, 835–842.
   PubMed Web of Science ®Google Scholar
• Shah S, Divekar AA, Hilchey SP, et al. (2005). Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer, 117, 574–586. doi:10.1002/ijc.21177.
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce A, et al. (2001). IFNgamma and lymphocytes prevent primary tumor development and shape tumor immunogenicity. Nature, 410, 1107–1111. doi:10.1038/35074122.
   PubMed Web of Science ®Google Scholar
• Sheen-Chen SM, Chen HS, Sheen CW, et al. (2001). Serum levels of transforming growth factor beta1 in patients with breast cancer. Arch Surg, 136, 937–940. doi:10.1001/archsurg.136.8.937.
   PubMed Web of Science ®Google Scholar
• Shen Y, Lu C, Tian W, et al. (2012). Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer. Int J Oncol, 40, 1285–1290. doi:10.3892/ijo.2011.1315.
   PubMed Web of Science ®Google Scholar
• Shim KS, Kim KH, Han WS, et al. (1999). Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer, 85, 554–561. doi:10.1002/(SICI)1097-0142(19990201)85:3<554::AID-CNCR6>3.0.CO;2-X.
   PubMed Web of Science ®Google Scholar
• Swann JB, Smyth MJ. (2007). Immune surveillance of tumors. J Clin Invest, 117, 1137–1146. doi:10.1172/JCI31405.
   PubMed Web of Science ®Google Scholar
• Tsushima H, Kawata S, Tamura S, et al. (1996). High levels of transforming growth factor-β1 in patients with colorectal cancer: association with disease progression. Gastroenterology, 110, 375–382. doi:10.1053/gast.1996.v110.pm8566583.
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Baratin M, et al. (2008). Functions of natural killer cells. Nat Immunol, 9, 503–510.
   PubMed Web of Science ®Google Scholar
• Yanaba K, Bouaziz JD, Haas KM, et al. (2008). A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity, 28, 639–650.
   PubMed Web of Science ®Google Scholar